Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
Código da empresaOCGN
Nome da EmpresaOcugen Inc
Data de listagemDec 03, 2014
CEOMusunuri (Shankar)
Número de funcionários95
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 03
Endereço11 Great Valley Parkway
CidadeMALVERN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal19355
Telefone14843284701
Sitehttps://ocugen.com/
Código da empresaOCGN
Data de listagemDec 03, 2014
CEOMusunuri (Shankar)
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados